The FDA said it agrees with the conclusions of the European Medicines Agency's Committee for Medicinal Products for Human Use that rejected a link between a class of diabetes drugs called incretin mimetics and increased risk of pancreatic adverse events including pancreatic cancer. "Our general view is that their conclusions are consistent with our current understanding of the data," the FDA's Center for Drug Evaluation and Research said.

Related Summaries